Bristol-Myers Squibb Co
BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Bristol-Myers Squibb Co News & Analysis
stocks
10 cheap wide-moat US stocks for 2025
Undervalued high-quality names from the Morningstar Wide Moat Focus Index are attractive stocks to buy for long-term investors.
stocks
10 best US blue-chip stocks to buy for the long term
The stocks of these high-quality companies with large market capitalisations look undervalued today.
personal-finance
US stock market outlook: tariffs are 2025's wild card
Macrodynamic tailwinds persist, but stocks are already priced to perfection. Will tariffs derail the market in 2025?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,922.00 | 4.90 | 0.05% |
| CAC 40 | 7,632.01 | 85.85 | 1.14% |
| DAX 40 | 23,757.69 | 331.72 | 1.42% |
| Dow JONES (US) | 44,173.64 | 585.06 | 1.34% |
| FTSE 100 | 9,128.30 | 59.72 | 0.66% |
| HKSE | 24,733.45 | 225.64 | 0.92% |
| NASDAQ | 21,053.58 | 403.45 | 1.95% |
| Nikkei 225 | 40,290.70 | 508.90 | -1.25% |
| NZX 50 Index | 12,797.07 | 113.03 | 0.89% |
| S&P 500 | 6,329.94 | 91.93 | 1.47% |
| S&P/ASX 200 | 8,663.70 | 1.70 | 0.02% |
| SSE Composite Index | 3,583.31 | 23.36 | 0.66% |